109. 非典型溶血性尿毒症症候群 Atypical hemolytic uremic syndrome Clinical trials / Disease details

臨床試験数 : 114 / 薬物数 : 36 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11

59 trials found

diseases per page:

Showing 1 to 10 of 59 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03999840 (ClinicalTrials.gov)	January 2021	25/6/2019	Eculizumab to Cemdisiran Switch in aHUS	A Phase II, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy o ...	Atypical Hemolytic Uremic Syndrome	Drug: cemdisiran;Drug: Placebos	Mario Negri Institute for Pharmacological Research	Alnylam Pharmaceuticals	Withdrawn	12 Years	N/A	All	0	Phase 2	Italy
2	EUCTR2018-004382-13-IT (EUCTR)	28/11/2019	25/05/2021	Safety and efficacy of Cemdisiran in athypical hemolytic uremic syndrome	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY O ...	Atypical Hemolytic Uremic Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term ...	Product Name: ALN-CC5 Product Code: [ALN-62643] INN or Proposed INN: Cemdisiran	IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI	NULL	Not Recruiting			Female: yes Male: yes	12	Phase 2	Italy
3	EUCTR2019-001619-21-ES (EUCTR)	07/10/2019	11/06/2019	OPTIMIZATION OF MAINTENANCE DOSE WITH ECULIZUMABACCORDING TO WEIGHT IN PATIENTS WITH ATYPIC HAEMOLIT ...	PILOT STUDY FOR THE OPTIMITZATION OF THE MAINTENANCE DOSE OF ECULIZUMABACCORDING TO THE WEIGHT IN AD ...	ATYPICAL HEMOLYTIC UREMIC SYNDROME MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term ...	Trade Name: SOLIRIS INN or Proposed INN: ECULIZUMAB	HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Spain
4	NCT03518203 (ClinicalTrials.gov)	August 3, 2018	5/3/2018	Eculizumabto Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multipl ...	Early Intervention With Eculizumabto Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Synd ...	Thrombotic Microangiopathies;Atypical Hemolytic Uremic Syndrome;Multiple Organ Dysfunction Syndrome	Drug: Eculizumab	Children's Hospital Medical Center, Cincinnati	NULL	Completed	N/A	N/A	All	23	Phase 2	United States
5	EUCTR2017-003916-37-GB (EUCTR)	13/04/2018	19/02/2018	Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)	Multicentre, open label, prospective, single arm study of the safety and impact of eculizumabwithdra ...	Atypical Haemolytic Uraemic Syndrome (aHUS);Therapeutic area: Diseases [C] - Immune System Diseases ...	Trade Name: Solaris Product Name: Solaris INN or Proposed INN: Eculizumab Other descriptive name: IgG2/ ...	Newcastle Upon Tyne Hospitals NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom
6	EUCTR2015-003135-35-DE (EUCTR)	20/06/2016	08/02/2016	EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, ...	EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, ...	atypical Hemolytic-Uremic Syndrome (aHUS) MedDRA version: 19.1;Level: LLT;Classification code 100195 ...	Trade Name: SOLIRIS Product Name: SOLIRIS INN or Proposed INN: ECULIZUMAB	Alexion Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 4	United Arab Emirates;United States;Spain;Israel;Russian Federation;United Kingdom;Italy;Czech Republ ...
7	NCT02574403 (ClinicalTrials.gov)	November 2015	5/10/2015	Study Assessing an Algorithm-based Strategy of EculizumabDiscontinuation in Children and Adults With ...	Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of EculizumabDiscon ...	Atypical Hemolytic Uremic Syndrome	Drug: eculizumab	Nantes University Hospital	NULL	Completed	3 Years	N/A	All	58	Phase 4	France
8	EUCTR2010-020326-18-FR (EUCTR)	25/03/2013	21/09/2010	AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMABIN ADULT PATIENTS WITH ATYPICAL HEMOLYTIC-UR ...	AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMABIN ADULT PATIENTS WITH ATYPICAL HEMOLYTIC-UR ...	Adult patients with Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 12.1;Level: LLT;Classi ...	Trade Name: SOLIRIS INN or Proposed INN: eculizumab Other descriptive name: Anti-C5 antibody	ALEXION PHARMACEUTICALS, INC.	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	France;Spain;Belgium;Netherlands;Germany;Italy;United Kingdom
9	NCT01757431 (ClinicalTrials.gov)	May 16, 2012	4/12/2012	The Safety and Efficacy of Eculizumabin Japanese Patients With Atypical Hemolytic Uremic Syndrome (a ...		Atypical Hemolytic Uremic Syndrome (aHUS)	Drug: Eculizumab	Alexion Pharmaceuticals	NULL	Completed	N/A	N/A	All	2	Phase 2	Japan
10	EUCTR2010-020310-28-BE (EUCTR)	09/11/2011	16/08/2011	-	AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMABIN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTI ...	Pediatric patients with Atypical Hemolytic-Uremic Syndrome (aHUS) MedDRA version: 14.0;Level: LLT;Cl ...	Trade Name: SOLIRIS INN or Proposed INN: eculizumab Other descriptive name: Anti-C5 antibody	ALEXION PHARMACEUTICALS, INC.	NULL	Not Recruiting			Female: yes Male: yes	15		United States;Canada;Spain;Belgium;Austria;Australia;Germany;Netherlands;Italy;United Kingdom

First Previous1 2 3 4 5 6Next Last